HK1213011B - Composition containing bacterium belonging to genus lactobacillus - Google Patents

Description

Composition containing lactobacillus

Technical Field

The present invention relates to a composition containing a bacterium belonging to the genus lactobacillus. More specifically, the present invention relates to a composition containing a novel Lactobacillus pentosus (Lactobacillus pentosus).

Background

Lactic acid bacteria and bifidobacteria have excellent physiological activities such as gastrointestinal regulation and immunopotentiation, and are used for various purposes depending on the characteristics of the bacteria. In particular, in recent years, many reports have been made on the progress of research for achieving the weight-reducing effect of these bacterial strains by taking them into the body.

For example, patent document 1 reports that Lactobacillus rhamnosus ATCC53103 decomposes a lipid (triacylglycerol) causing obesity and inhibits its absorption in the body, and that after living bacteria l.brevis KB290, which is one of plant lactic acid bacteria, reach the intestine, it is known that the intestinal survival rate and intestinal tract reaching ability are excellent (but the number of excreted bacteria is smaller than the number of ingested bacteria) (see non-patent document 1). further, non-patent document 2 reports that Lactobacillus acidophilus L-92 is excellent in intestinal tract reaching ability in which the strain is obtained by recovering from feces at 93% of the number of ingested bacteria, and non-patent document 3 reports that the intestinal tract survival ability of l.gasseri SBT2055 is excellent and that when 100g of Lactobacillus acidophilus SBT2055 is administered⁶～5×10⁶cfu/g fermented milk, 1 × 10 was detected at most from feces⁵L.gasseri SBT2055 around cfu/g.

On the other hand, the following are reported about bifidobacterium: bifidobacterium animalis subsp. lactis GCL2505 strain has an intestinal reach property that viable bacteria reach the intestinal tract after oral ingestion, and exhibits a significant intestinal proliferation property (see patent document 2). The following non-patent document 4 reports as follows: DN-173010, which is about 20% of the number of ingested bacteria, was detected in feces when B.animalis ssp.lactis DN-173010 was administered to an adult.

Documents of the prior art

Patent document

Japanese patent application laid-open No. 2011-206057 of patent document 1

Japanese patent application laid-open No. 2011-

Non-patent document

Non-patent document 1 "health function and application of lactic acid bacterium" (Japanese original name "health care function and application of lactic acid bacterium at bone site と") (page 160 and 162 published by CMC (applied date, 8 and 31) at 2007, 8 and 31

Non-patent document 2 journal of the Japanese society for lactic acid bacteria (Japanese name: Japanese society for lactic acid bacteria ) No. 12 2001 "isolation and Properties of Lactobacillus acidophilus L-92 Strain having excellent persistence in human intestinal tracts" (Japanese name: ヒト Ostrin for property of い (better) (とそ) of で strain having residual ability in < 3526 > Oseltia

Nonpatent document 3Microbiol. Immunol.2006 No. 50 "Monitoring and simulation of Lactobacillus gasseri SBT2055 in the human endogenous extract," 867-

Non-patent document 4J. mol. Microbiol. Biotechnol.2008 No. 14 "simulation of Bipolar analysis DN-173010 in the mechanical microbial amplification in solubilized form or in a transferred product-a transferred polypeptide in synthesized synthesis of metals additives", page 128-136

Disclosure of Invention

However, since fat absorption is mainly performed in the small intestine, the bifidobacterium, which generally grows in the large intestine, shows an intestinal proliferation property and thus does not sufficiently suppress fat absorption. In addition, although lactic acid bacteria are known to act on the upper end of the large intestine, no bacterial species showing proliferation in the intestine have been reported.

The present invention addresses the problem of providing a composition containing a lactic acid bacterium that exhibits intraintestinal proliferation.

The present invention relates to a composition containing lactobacillus pentosus strain TUA4337L (accession No. NITEBP-1479) having an ability to proliferate in the intestinal tract.

The composition of the present invention has an excellent effect of increasing the physiological activity of the bacterial cells by proliferating lactic acid bacteria having a proliferation ability in the intestinal tract when ingested, and further producing a weight-reducing effect.

Drawings

FIG. 1 is a graph showing the results of screening in artificial intestinal juice.

Fig. 2 is a graph showing the progress of weight gain. The "+" marks in the figure indicate significant differences (p <0.05) relative to the high fat diet group.

FIG. 3 is a graph showing the amount of triglycerides in serum. The "+" marks in the figure indicate significant differences (p <0.05) relative to the high fat diet group.

Detailed Description

The composition of the invention has the following important characteristics: that is, a lactic acid bacterium containing lactobacillus pentosus strain TUA43 4337L having an ability to proliferate in the intestinal tract (hereinafter, also referred to as the lactic acid bacterium of the present invention).

The lactic acid bacterium of the present invention is lactobacillus pentosus strain TUA4337L, which is characterized by having a growth ability in the intestinal tract. In the present specification, "having a growth ability in an intestinal tract" or "growing in an intestinal tract" means that the cells grow in the small intestine and/or the large intestine, preferably in the small intestine after reaching the intestinal tract, and the degree of growth ability can be evaluated as "having a growth ability" in the following cases: that is, the culture is cultured in artificial intestinal juice at 37 deg.C for 6hr, relative to OD at inoculation₆₆₀Showing a value of 10 times or more.

The present inventors have conducted studies on the proliferation ability of about 480 kinds of lactic acid bacteria retained by the present inventors in artificial intestinal juice, and have found that when a suspension of lactobacillus pentosus selected from them is administered to an animal, the number of excreted bacteria of lactobacillus pentosus strain TUA4337L is significantly increased compared to the number of administered bacteria, and have completed the present invention.

Lactobacillus pentosus strain TUA4337L identified as NRIC 0883 under accession number NITE BP-1479, deposited at the national institute of advanced technology for evaluation of the products (NITE) patent microorganism depositary (Kazusa falciparum 2-5-8, Kyowa prefecture, Kyowa, Japan) on 12/10/2012 of International depositary. Hereinafter, the strain Lactobacillus pentosus TUA4337L will be referred to as TUA4337L strain.

The mycological properties of the TUA43 4337L strain are shown in tables 1 and 2. The assimilation of sugars in Table 2 is determined using the bacterial identification kit API 50CH (BIOMETRIEUX). Furthermore, "+" in Table 2 means assimilable saccharide, and "-" means non-assimilable saccharide.

[ Table 1]

Form of the bacterium	Bacillus
		Gram staining property	Positive for
Movement property	Is free of
		Spore	Is free of
Spores	Is free of
		Catalase reaction	Is free of
Propagation at 15 ℃	○
		Propagation at 40 ℃	○
Aerobic propagation	○
		Anaerobic propagation	○
Propagation pH	3.0～12.5

[ Table 2]

The TUA43 4337L strain is described in detail in examples below, and is characterized by having an increased number of excreted bacteria relative to the number of ingested bacteria, i.e., having an intestinal proliferation activity. The in-intestine growth ability is, for example, a number of bacteria preferably 10 times or more, more preferably 15 times or more, further preferably 20 times or more, and still further preferably 25 times or more, based on the number of bacteria at the start of culture, after culturing in an artificial intestinal juice at 37 ℃ for 6 hours.

In addition, the recA gene sequence (SEQ ID NO: 1) encoded by the DNA extracted from TUA4337L strain was 99% identical to the recA gene sequence of Lactobacillus pentosus IG1 strain. In The present specification, The similarity is expressed by a score using, for example, a search program BLAST which uses an algorithm developed by Altschul et al (The Journal of Molecular Biology, 215, 403-.

The medium for culturing the TUA4337L strain is not particularly limited, and may be a medium containing a carbon source, a nitrogen source, inorganic salts, organic nutrients, and the like. In addition, the culture can be carried out in an agar medium or a liquid medium. The culture temperature is preferably 10 to 45 ℃, more preferably 15 to 42 ℃, further preferably 28 to 38 ℃, further preferably 35 to 37 ℃, and the pH value for proliferation is preferably 3.0 to 12.5, more preferably 3.5 to 12.0.

The composition of the present invention contains lactobacillus pentosus strain TUA43 4337L having an ability to proliferate in the intestinal tract as described above in various forms.

Examples of the form of lactobacillus pentosus strain TUA43 4337L contained in the composition of the present invention include lactobacillus (living or dead) itself, lactobacillus-containing materials, and lactobacillus-treated materials. The viable bacteria can be obtained from lactobacillus-containing material such as lactobacillus culture solution. The dead bacteria can be obtained by, for example, heating, ultraviolet irradiation, formalin treatment, acid treatment, or the like of the live bacteria. The obtained viable bacteria and dead bacteria can be further ground and crushed to obtain treated product. In addition, from the viewpoint of sufficiently exerting the growth effect in the intestinal tract, live bacteria are preferable as the lactic acid bacteria in the above-described forms, but dead bacteria may be mixed.

Examples of the lactic acid bacteria include live bacteria, wet bacteria, and dry bacteria. Examples of the lactic acid bacteria-containing material include a lactic acid bacteria suspension, a lactic acid bacteria culture (including a bacterial cell, a culture supernatant, and a culture medium component), and a lactic acid bacteria culture solution (a material obtained by removing a solid component from a bacterial cell culture). Examples of the lactic acid bacteria-treated product include ground products, crushed products, liquid products (such as an extract), concentrates, slurries, dried products (such as a spray-dried product, a freeze-dried product, a vacuum-dried product, and a centrifugally-dried product), and diluted products.

The Lactobacillus pentosus strain TUA4337L of the present invention may be used alone or in combination of 2 or more types as long as it has the ability to proliferate in the intestinal tract, but the total content of the composition of the present invention is not particularly limited, but is usually 0.00001 to 99.9% (g/g), particularly preferably 0.0001 to 50% (g/g), or the number of cells is preferably 1.0 × 10²～1.0×10¹²In the range of 1.0 × 10, more preferably 1.0 g/g⁶～1.0×10¹²In units/g. If the bacteria are live bacteria, the "number/g" can be expressed as "CFU/g". In addition, the lactic acid bacteria of the present invention may also be used in combination with a strain having an action other than intestinal proliferation.

The composition of the present invention may contain a carrier, a base, and/or an additive, etc. generally used in the food field, the pharmaceutical field, etc., within a range not to impair the effect of the present invention, as long as the composition contains lactobacillus pentosus strain TUA4337L having the ability to proliferate in the intestinal tract. Specifically, known ingredients such as sweeteners, acidulants, vitamins, and the like, excipients, binders, disintegrants, lubricants, flavoring agents, solubilizers, suspending agents, coating agents, stabilizers, and the like can be mentioned.

The composition of the present invention may contain 1 or 2 or more kinds of known components such as a cosmetic component, a lifestyle-related disease preventing and improving component, and the like, as necessary, in order to add other useful effects.

The form of the composition of the present invention is not particularly limited as long as it is a form capable of ingesting lactobacillus pentosus strain TUA43 4337L having an intestinal growth ability into the body, and from the viewpoint of the effect of the strain, a beverage or food containing the strain is exemplified; from the viewpoint of easy ingestion, an ingestible tablet form as a supplement, and the like are exemplified. Specifically, for example, various forms such as tablets, capsules, beverages, seasonings, processed foods, sweets, and pastries can be cited. Of these forms, it is preferably provided as a fermented food. The fermented food is a general term for food fermented with vegetable lactic acid bacteria, and beverages are also included therein. The type of the fermented food is not particularly limited, and examples thereof include fermented foods such as fermented milk, lactic acid bacteria beverage, fermented soybean milk, pickled product, pickled cabbage, fruit wine, sauce, soy sauce, and fermented fruit juice yogurt obtained by fermenting fruits or vegetables, fruit juice, vegetable juice, and the like.

Further, it is considered that a drink or food containing the lactic acid bacterium of the present invention, that is, a drink or food containing lactobacillus pentosus strain TUA4337L having an ability to proliferate in the intestinal tract, exhibits a higher fat absorption inhibitory action and sustains the action when consumed as compared with when a lactic acid bacterium having no ability to proliferate in the intestinal tract is consumed, and therefore, as a health functional food or a health food having a sustained fat absorption inhibitory action, it is possible to provide a substance to be used in the following applications: for example, it is used for inhibiting weight gain or weight loss, or for preventing obesity or improving obesity, or for losing weight. Here, the health functional food means a health functional food prescribed by the ministry of health and labor, including a nutritional functional food and a specific health food, and may be any of a food and a drink as a health functional food and a health food.

The composition of the present invention may be prepared by a known method in the fields of foods, preparations and the like, depending on the form thereof.

The composition of the present invention may be appropriately set depending on the form and purpose of ingestion thereof, and the age, body weight, symptom and the like of the subject to ingest the composition, and is not fixed, and for example, the amount of lactic acid bacteria is preferably 1.0 × 10 on average for 1 day⁶More than one per kg body weight, is taken orally in 1 to several times. The amount of the bacterial cells taken in 1 day is preferably 0.00001 to 1g, more preferably 0.0001 to 0.2g, and still more preferably 0.0003 to 0.002g in dry weight, based on about 50kg of the weight of 1 adult. For example, the composition of the present invention has the effect of inhibiting fat absorption due to the lactic acid bacteria of the present inventionAnd has a growth ability in the intestinal tract, and therefore, it is possible to ingest lactic acid bacteria in an amount within the above range together with or before eating a high-fat food, and it is also possible to ingest 1 day 1 after breakfast because it can produce a sustained fat absorption inhibitory effect. In the present specification, "ingestion" means "ingestion" and/or "administration".

As the subject to be ingested in the present specification, a human requiring a fat absorption inhibitory effect is preferable, but a pet animal or the like may be used.

Thus, by ingesting the composition of the present invention, absorption of fat from the intestinal tract can be suppressed. Therefore, the present invention also provides a fat absorption inhibitor consisting of lactobacillus pentosus for inhibiting absorption of fat from food from the intestinal tract and having a proliferation ability in the intestinal tract.

The present invention also provides a method for inhibiting fat absorption, which comprises administering an effective amount of a composition containing the aforementioned lactobacillus pentosus strain TUA4337L to an individual in need of fat absorption inhibition.

The subject in need of fat absorption inhibition is not particularly limited as long as the disease is one whose therapeutic effect can be observed by inhibiting fat absorption. For example, an individual who is obese or who is obese and has a disease such as diabetes, hyperlipidemia, high blood pressure, or arteriosclerosis may be exemplified. For the purpose of preventing or ameliorating the above-mentioned diseases, for example, an individual who is conscious of weight, blood glucose level, or blood pressure may be included in the above-mentioned individuals.

The effective amount is an amount that inhibits fat absorption when TUA43 4337L strain is administered to the above-mentioned subject, compared with the subject to which no such administration is given. The specific effective amount is appropriately set depending on the administration form, administration method, purpose of use, age, body weight, symptom, and the like of the individual, and is not fixed. In the present specification, administration includes all modes of administration, ingestion, taking and drinking.

Examples

The following examples are given to specifically illustrate the present invention, but the present invention is not limited to the following examples.

Example 1< screening Using growth Capacity in Artificial intestinal juice as an index >

The present inventors evaluated the growth ability in artificial intestinal juice of about 480 strains (including JCM strain) of lactic acid bacteria mainly comprising a plant-derived lactic acid bacteria among the lactic acid bacteria retained.

Specifically, glycerol-preserved bacteria of each lactic acid bacterium were inoculated at 1 v/v% into MRS medium (Difco laboratories) (10mL), and cultured at 35 ℃ for 16 to 17 hr. Next, the OD of each culture solution was measured with a spectrophotometer UV-1600 (Shimadzu Co., Ltd.)₆₆₀(absorbance at 660 nm), 100. mu.L of MRS medium was used as OD of each culture solution₆₆₀The culture solution prepared for 10 was inoculated into an artificial intestinal solution (10mL) having the composition shown below. Thereafter, the cells were cultured at 37 ℃ for 6hr with slow shaking, and then OD was measured₆₆₀And determining proliferation rate (OD after 6 hr)₆₆₀OD at inoculation₆₆₀). Representative screening results are shown in table 3 and fig. 1.

< Artificial intestinal juice (pH6.45) >

MRS Medium 9mL

1mL of 10 w/v% bile (Wako pure chemical industries, Ltd.) solution

100 μ L of 1 w/v% pancreatin (from Porcine: SIGMA)

In addition, as the bile solution and the pancreatin solution, sterile bile solution and pancreatin solution treated with 0.22 μm filter paper (PVDF membrane, manufactured by Millipore Co., Ltd.) were used.

[ Table 3]

From the results, it was found that lactobacillus pentosus and lactobacillus plantarum tend to increase in proliferation rate, and among them, lactobacillus pentosus strain TUA4337L has particularly high proliferation rate and excellent proliferation performance in intestinal tracts.

Example 2< evaluation of intestinal tube growth ability in vivo >

Specifically, about 10 million cells (1.0 × 10 am) were administered to mice freely ingesting high-fat food using the administration samples prepared as follows (TUA 4337L strain prepared as follows)⁹cells) aliquots (equivalent to 250 μ L of bacterial suspension) of lactic acid bacteria were administered 1 time (n-5) to C57BL/6J mice (10 weeks old, male).

< preparation of administration sample (viable bacteria-containing sample) >

[ 1] Glycerol-storing bacteria of TUA4337L Strain were inoculated at 1 v/v% into MRS medium (30mL)

[ 2] culture (35 ℃, 20hr)

[ 3] the culture was centrifuged (8000rpm, 5min) to remove the supernatant, and the supernatant was suspended in 30mL of PBS (-)

[ 4] the suspension of [ 3] was centrifuged (8000rpm, 5min) and the supernatant was removed, followed by resuspension in 5mL of PBS (-)

[ 5] counting of bacteria by microscope

[ 6] A bacterial suspension (prepared from PBS (-) for liquid feeds) was prepared by dividing a 200-hundred million cells solution into 15-mL centrifuge tubes, centrifuging (8000rpm, 5min) to remove the supernatant, and suspending the supernatant in 5-mL liquid feeds (60 kcal% FAT for high FAT Diet: Research Diet)

Thereafter, 2 days of whole-bezoar were collected 4 times (afternoon, and afternoon on the day of the start of the experiment), the number of bacteria in each whole-bezoar was quantified by the following method, and the intestinal increase rate of TUA4337L strain (number of bacteria in each whole-bezoar/number of administered bacteria) in each mouse was calculated. The results are shown in Table 4.

< determination of the number of bacteria by real-time PCR >

[ 1] after adding 1mL of PBS (-) to 100mg of (wet-heavy) bezoar, the mixture was broken by a spatula

[ 2] after collecting 100mg of bezoar using Eppendorf tube (registered trademark), centrifugation (15000rpm, 5min) and removal of supernatant, suspension with 1mL of PBS (-) was performed (operation from centrifugation to suspension was repeated 2 times)

[ 3] after removing the supernatant from the suspension of [ 2], DNA was extracted with a Kit (QIAamp DNA stock Mini Kit: QIAGEN) (cell disruption was performed 3 times by adding 300mg of Glass BEADS (150 to 212. mu.m: SIGMA), 300. mu.L of phenol/chloroform/isoamoylalcohol (25: 24: 1) and 900. mu.L of buffer ASL (reagent in Kit), centrifuging at 3000rpm and 1min with MULTI-BEADS SHOCKER MB-200(YASUI KIKAI), and then standing on ice for 1min)

[ 4] quantification of lactic acid bacteria in intestinal tract contents by real-time PCR under the conditions shown below

(real-time PCR conditions)

(1) 10. mu.L of SYBR Premix Ex Taq ll (Takara Bio), 0.8. mu.L of reach primer (10. mu.M), 0.4. mu.L of ROX reference DyeII, 6. mu.L of sterilized water, and 2. mu.L of the DNA solution were mixed to prepare a PCR reaction solution. The following primers (the 16S rDNA sequences of Lactobacillus pentosus and Lactobacillus plantarum are 100% identical) were used to specifically detect the 16S rDNA of Lactobacillus pentosus and Lactobacillus plantarum.

primer 1: 5'-GCAAGTCGAACGAACTCTGGTATT-3' (Serial number 2)

primer 2: 5'-CGGACCATGCGGTCCAA-3' (SEQ ID NO. 3)

(2) PCR was carried out using 7500Real Time PCR System (Applied Biosystems), 95 ℃ for 30 seconds, 60 ℃ for 5 seconds, and 34 seconds as 1 cycle, and 60 cycles were counted to obtain the number of copies of the content per 1g of the intestinal tract from the fluorescence intensity, the total amount of the content in the intestinal tract, and the dilution ratio.

(3) The copy number of 16S rDNA per 1 cell was also determined and converted into the number of bacteria. In addition, it was confirmed that neither lactobacillus pentosus nor lactobacillus plantarum was detected by the real-time PCR in mice to which no lactobacillus was administered.

[ Table 4]

Example 3< weight gain inhibitory Effect >

C57BL/6J mice (8 weeks old, male) were divided into the following 4 groups: generally, a food group, a high-fat food + live group, a high-fat food + dead group (each n ═ 10), and the foods shown in table 5 below were fed for 32 days, respectively, and the body weights were measured and the average values were calculated every day. The transition of the average value is shown in fig. 2. In addition, group comparisons were performed using a t-test at a significance level of 0.05.

Specifically, each solid food was freely ingested by each group in table 5. The high-fat food + live bacteria group was a sample for administration prepared in the same manner as in example 2, and the high-fat food + dead bacteria group was a sample for administration prepared as follows, and each of the samples was administered with an amount of about 10 hundred million cells per day of lactic acid bacteria. On the other hand, 250. mu.L of PBS (-) without lactic acid bacteria was administered to the diet group, and 250. mu.L of liquid feed without lactic acid bacteria was administered to the high-fat diet group.

[ Table 5]

*10kcal％FAT(Research Diet)

60kcal％FAT(Research Diet)

< preparation of administration sample (sample containing dead bacteria) >

[ 1] Glycerol-storing bacteria of TUA4337L Strain were inoculated at 1 v/v% into MRS medium (30mL)

[ 2] culture (35 ℃, 20hr)

[ 3] the culture was centrifuged (8000rpm, 5min) to remove the supernatant, and the supernatant was suspended in 30mL of PBS (-)

[ 4] the suspension of [ 3] was centrifuged (8000rpm, 5min) and the supernatant was removed, followed by resuspension in 5mL of PBS (-)

[ 5] counting of bacteria by microscope

[ 6] A200-hundred million cells solution was dispensed into a 15-mL centrifuge tube, centrifuged (8000rpm, 5min) to remove the supernatant, added with 5mL artificial gastric juice (125mM NaCl, 7mM KCl, pH1.0), stirred, and allowed to stand for 60min

[ 7 ] the solution of [ 6] was centrifuged (8000rpm, 5min) to remove the supernatant, and then suspended in 5mL of liquid feed (60 kcal% FAT) to prepare a bacterial suspension

As a result, a significant weight gain inhibitory effect of the TUA4337L live bacteria-administered group was shown relative to the control (high-fat food group). And live bacteria administration is more effective than dead bacteria administration. It is considered that lactobacillus pentosus strain TUA4337L effectively affects the host by proliferating in the intestinal tract.

Example 4< fat absorption inhibitory Effect >

The same contents of food as in example 3 were fed for 2 weeks with the group structure of normal food group, high fat food group, and high fat food + live bacteria group (each n is 12) in example 3. Thereafter, after fasting overnight, olive oil (nacalaitesque) administration (5mL/kg) was performed, and after 3 hours, dissection and serum was collected from the great vein. Triglyceride (TG) in serum was measured by using triglyceride E-test Wako (Wako pure chemical industries, Ltd.). The results are shown in FIG. 3. In addition, group comparisons were judged by t-test for significant differences from a significant level of 0.05.

As a result, a significant tendency to increase TG in blood was confirmed in the high-fat diet group relative to the normal diet group. Therefore, it is considered that if a high-fat food is continuously consumed, it becomes a body that easily absorbs fat. In addition, the inhibition of increase in TG in blood was confirmed in the TUA43 4337L live cell administered group relative to the control (high fat diet group). Therefore, it is presumed that fat absorption inhibition is one of the mechanisms of the weight gain inhibition effect, and that the effect is already effective 1 day after the start of live bacterial administration of TUA4337L, and that the effect is continuously exhibited.

The following is an example of a specific formulation of a composition containing lactobacillus pentosus strain TUA4337L of the present invention.

Production example 1: tablets ]

A pharmaceutical (tablet) containing the strain TUA4337L was produced according to the following method.

66.7g of the dry and pulverized product of TUA4337L was mixed with 232.0g of lactose and 1.3g of magnesium stearate, and the mixture was tableted with a single punch tablet machine to prepare tablets having a diameter of 10mm and a weight of 300 mg.

Production example 2: yogurt

A mixture of milk, skim milk powder and water was prepared, heated to sterilize, cooled to about 40 ℃ and inoculated with TUA43 4337L strain as a starting material, and then placed in a fermentation chamber to be left to ferment. Here, the temperature for the standing fermentation can be appropriately selected. Further, in order to control the dissolved oxygen concentration at the start of fermentation, an inert gas such as nitrogen may be exchanged. The thus-obtained TUA4337L fermented milk was added to commercially available milk, and left to stand for 3 days to prepare yogurt.

Production example 3: lactobacillus beverage

The raw materials shown in table 6 were mixed with strain TUA4337L to prepare a lactic acid bacteria beverage.

[ Table 6]

Composition of	Parts by weight
		TUA43 4337L fermented milk with milk solids content 21%	14.76
Fructose glucose liquid sugar	13.31
		Pectin	0.5
Citric acid	0.08
		Perfume	0.15
Water (W)	71.2
		Total amount of	100

Production example 4: fruit juice fermented beverage, vegetable juice fermented beverage

Peach juice was inoculated with 2 wt% of TUA4337L and cultured at 30 ℃ for 38 hours to prepare peach fermented juice. In addition, carrot fermented juice obtained by fermenting carrot juice was similarly prepared.

Industrial applicability

The composition of the present invention contains lactic acid bacteria having a growth ability in the intestine, and thus, when ingested into the body, the lactic acid bacteria can inhibit fat absorption and weight gain by growing after reaching the intestine, and thus can be applied for the purpose of a weight-reducing effect.

Sequence Listing free content

Sequence No. 1 of the sequence listing is the base sequence of recA of Lactobacillus pentosus TUA 4337L.

The sequence number 2 in the sequence table is a base sequence of the lactobacillus pentosus/lactobacillus plantarum specific primer.

Sequence number 3 in the sequence table is a base sequence of the lactobacillus pentosus/lactobacillus plantarum specific primer.

Claims (26)

1. A composition comprising Lactobacillus pentosus strain TUA4337L having an intestinal proliferation potency under accession number NITE BP-1479.

2. The composition according to claim 1, which has an effect of inhibiting absorption of fat from the intestinal tract.

3. The composition of claim 1, wherein fat absorption in the intestinal tract resulting from a high fat diet is inhibited.

4. The composition of claim 2, wherein fat absorption in the intestinal tract resulting from a high fat diet is inhibited.

5. The composition according to claim 1, wherein Lactobacillus pentosus TUA4337L strain proliferates in the intestinal tract upon consumption, thereby exerting a fat absorption inhibitory effect stronger than that upon consumption of a lactic acid bacterium having no proliferation ability.

6. The composition according to any one of claims 2 to 4, wherein Lactobacillus pentosus TUA43 4337L strain proliferates in the intestinal tract upon consumption, thereby exerting a stronger fat absorption inhibitory effect than when lactic acid bacteria having no proliferation ability are consumed.

7. The composition according to claim 1, wherein the Lactobacillus pentosus TUA4337L strain proliferates in the intestinal tract upon consumption, thereby maintaining the fat absorption inhibitory effect as compared to when the lactic acid bacteria having no proliferation ability are consumed.

8. The composition according to any one of claims 2 to 5, wherein the Lactobacillus pentosus strain TUA43 4337L proliferates in the intestinal tract upon consumption, thereby maintaining the fat absorption inhibitory effect as compared to when the lactic acid bacteria having no proliferation ability are consumed.

9. The composition according to claim 1, for use in weight gain inhibition or weight loss.

10. The composition according to any one of claims 2 to 5 and 7, for use in weight gain inhibition or weight reduction.

11. The composition according to claim 1, for use in obesity prevention or obesity improvement.

12. The composition according to any one of claims 2 to 5, 7 and 9, for use in obesity prevention or obesity improvement.

13. The composition of claim 1, for use simultaneously with and/or prior to consumption of the high fat food.

14. Composition according to any one of claims 2-5, 7, 9 and 11, for use simultaneously with and/or before the consumption of a high-fat food.

15. The composition of claim 1, which is a beverage or a food.

16. Composition according to any one of claims 2-5, 7, 9, 11 and 13, characterized by being a beverage or a food product.

17. The composition of claim 1, wherein the composition is yogurt.

18. Composition according to any one of claims 2 to 5, 7, 9, 11, 13 and 15, characterized in that it is a yoghurt.

19. The composition of claim 1, which is an inhibitor of absorption of fat from food from the intestinal tract.

20. The composition according to any one of claims 2-5, 7, 9, 11 and 13, characterized by being an inhibitor of the absorption of fat from food from the intestinal tract.

21. The composition of claim 1, wherein the composition is consumed 1 time a day before breakfast.

22. The composition according to any one of claims 2-5, 7, 9, 11, 13, 15, 17 and 19, wherein 1 is consumed 1 time a day before breakfast.

23. The composition according to any one of claims 1-5, 7, 9, 11, 13, 15, 17, 19 and 21, for weight loss.

24. A composition for use in inhibiting fat absorption, which comprises Lactobacillus pentosus TUA4337L strain having an ability to proliferate in intestinal tracts and deposited as NITE BP-1479.

25. Use of a composition comprising lactobacillus pentosus strain TUA4337L having an ability to proliferate in intestinal tracts under accession number NITE BP-1479 for the purpose of inhibiting fat absorption.

26. A method for inhibiting fat absorption, which comprises administering a composition comprising an effective amount of Lactobacillus pentosus TUA4337L strain having an ability to proliferate in the intestinal tract and deposited as NITE BP-1479 to a subject in need of fat absorption inhibition.